Benzinga's analyst ratings data shows GILD with a Neutral consensus rating.

Morgan Stanley recently maintained Gilead Sciences with an Equal-Weight and raised the price target from $81 to $85.

Josh Brown of Ritholtz Wealth Management named Berkshire Hathaway Inc. (NYSE: BRK-B) (NYSE: BRK-A) as his final trade.

Don’t forget to check out our premarket coverage here

Jim Lebenthal of Cerity Partners said Wynn Resorts, Limited (NASDAQ:WYNN) looks like it’s breaking out right now.

Shares of casino stocks traded higher on Thursday in sympathy with Las Vegas Sands Corp. (NYSE:LVS), which reported better-than-expected quarterly results.

Amy Raskin of Chevy Chase Trust said Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) stock has been in a strong trend.

Vertex recently announced Health Canada market authorization for ORKAMBI in children with cystic fibrosis between ages 1 to less than 2 years of age.

Price Action: Berkshire Hathaway shares rose 0.2% to close at $323.82, while Gilead Sciences gained 0.7% to settle at $84.69 on Thursday. Vertex Pharmaceuticals gained 0.2% to $329.15, while Wynn Resorts added 1.4% to $113.69 during the session.

Check This Out: Citigroup, Dell And 2 Other Stocks Insiders Are Selling